A membrane capture assay for lipid kinase activity

Nature Protocols

Volumn 2, Issue 10, 2007, Pages 2459-2466

  Knight, Zachary A ^a,d   Feldman, Morri E ^b   Balla, Andras ^c   Balla, Tamas ^c   Shokat, Kevan M ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 KINASE; PYROXYLIN;

ANIMAL; ARTICLE; ARTIFICIAL MEMBRANE; CHEMISTRY; COMPUTER PROGRAM; DRUG ANTAGONISM; ENZYME SPECIFICITY; METABOLISM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; COLLODION; ENZYME INHIBITORS; MEMBRANES, ARTIFICIAL; PHOSPHATIDYLINOSITOLS; SOFTWARE; SUBSTRATE SPECIFICITY;

EID: 38449095987     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2007.361     Document Type: Article

References (31)

1. Katso, R. et aL Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biot. 17, 615-675 (2001).
2. Maehama, T. & Dixon, J.E. Thetumorsuppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J. Biol. Chem. 273, 13375-13378 (1998).
3. Gupta, S. et al. Binding ofras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129, 957-968 (2007).
4. Rodriguez-Viciana, P. et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89, 457-467 (1997).
5. Rodriguez-Viciana, P. et aL. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 527-532 (1994).
6. Samuels, Y. et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
7. Karakas, B., Bachman, K.E. & Park, B.H. Mutation of the PIK3CA oncogene in human cancers. Br. J. Cancer 94, 455-459 (2006).
8. Chow, L.M. & Baker, S.J. PTEN function in normal and neoplastic growth. Cancer Lett. 241, 184-196 (2006).
9. Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated inhuman brain, breast, and prostate cancer. Science 275, 1943-1947 (1997).
10. Okkenhaug, K. et al. Impaired B and Tcellantigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297, 1031-1034 (2002).
11. Ali, K. et aL. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431, 1007-1011 (2004).
12. Wymann, M.P. et al. Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy. Biochem. Soc. Trans. 31, 275-280 (2003).
13. Hirsch, E. et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287, 1049-1053 (2000).
14. Camps, M. et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11, 924-955 (2005).
15. Barber, D.F. et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11, 933-935 (2005).
16. Knight, Z.A. & Shokat, K.M. Chemically targeting the PI3K family. Biochem. Soc. Trans. 35, 245-249 (2007).
17. Gray, A., Olsson, H., Batty, I.H., Priganica, L. & Peter Downes, C. Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. AnaL. Biochem. 313, 234-245 (2003).
18. Knight, Z.A. et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. CeLL 125, 733-747 (2006).
19. Knight, Z.A. et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg. Med. Chem. 12, 4749-4759 (2004).
20. Balla, T. et al. Isolation and molecular cloning of wortmannin-sensitive bovine type III phosphatidylinositol 4-kinases. J. BioL. Chem. 272, 18358-18366 (1997).
21. Meyers, R. & Cantley, L.C. Cloning and characterization ofawortmannin-sensitive human phosphatidylinositol 4-kinase. J. BioL. Chem. 272, 4384-4390 (1997).
22. Nakagawa, T., Goto, K. & Kondo, H. Cloning and characterization of a 92 kDa soluble phosphatidylinositol 4-kinase. Biochem. J. 320 (Part 2): 643-649 (1996).
23. Nakagawa, T., Goto, K. & Kondo, H. Cloning, expression, and localization of 230-kDa phosphatidylinositol 4-kinase. J. BioL. Chem. 271, 12088-12094 (1996).
24. Ishihara, H. etai Type I phosphatidylinositol-4-phosphate 5-kinases. Cloning of the third isoform and deletion/substitution analysis of members of this novel lipid kinase family. J. BioL Chem. 273, 8741-8748 (1998).
25. Ishihara, H. et al. Cloning of cDNAs encoding two isoforms of 68-kDa type I phosphatidylinositol-4-phosphate 5-kinase. J. BioL. Chem. 271, 23611-23614
26. Rameh, L.E., Tolias, K.F., Duckworth, B.C. & Cantley, L.C. A new pathway for synthesis of phosphatidylinositol-4, 5-bisphosphate. Nature 390, 192-196
27. Carpenter, C.L. et aL. Purification and characterization of phosphoinositide 3-kinase from rat liver. J. Biot. Chem. 265, 19704-19711 (1990).
28. Knight, Z.A. & Shokat, K.M. Features of selective kinase inhibitors. Chem. BioL. 12, 621-637 (2005).
29. Cheng, Y. & Prusoff, W.H.: Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108 (1973).
30. Traut, T.W.: Physiological concentrations of purines and pyrimidines. Mot. Celt. Biochem. 140, 1-22 (1994).
31. Gribble, F.M. et al. A novel method for measurement of submembrane ATP concentration. J. Biot. Chem. 275, 30046-30049 (2000).